Log in | Jump |
Biomedical investment and business development chatter





Archives

This post was commissioned on October 6, 2008, and it was categorized as M&A.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

The WSJ is reporting this morning Eli Lilly has inked a $6.5B deal to buy ImClone.

I guess the Swami was right.

Theoretically Related Posts

This post was constructed by .

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
_blank _blank _blank _blank _blank _blank _blank

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

 

Trackbacks

(Trackback URL)

close Reblog this comment
blog comments powered by Disqus